HARLAN F. WEISMAN, M.D. CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Dr. Weisman has served as our Chairman and CEO since January 2013, and has served as a member of our board of directors since August 2012. Dr. Weisman has over 20 years of experience as a senior healthcare executive and physician responsible for the development, regulatory approval and launch of innovative biopharmaceutical, medical device and diagnostic products. Most recently, Dr. Weisman was Chief Science and Technology Officer for Medical Devices and Diagnostics at J&J. In that role, he was a member of the Medical Devices and Diagnostics Group Operating Committee steering the group’s scientific and technical agendas, including investments in group-level technologies, and sponsoring the research and development talent agenda. Before serving as Chief Science and Technology Officer for Medical Devices and Diagnostics, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals, where he had executive oversight of the ALZA Corporation, J&J Pharmaceutical Research and Development, and TransForm Pharmaceuticals, Inc. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Dr. Weisman was the Founder and Managing Director of And-One Consulting, LLC, a firm that assists life sciences companies develop global strategies aimed at accelerating medical product development, regulatory approval and market acceptance. Prior to joining industry, Dr. Weisman was an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine. Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine. After his residency in Internal Medicine at Mount Sinai Hospital in New York, he did his post-graduate fellowship training in cardiovascular disease at Johns Hopkins Medical institutions.
Noah D. Beerman Executive Vice President & Chief Operating Officer
Mr. Beerman has served as our executive vice president and chief operating officer since September 2011 and has over 25 years of experience in the biopharmaceutical industry. Mr. Beerman, who has been a consultant to our company since May 2011, served as president and chief executive officer and a director of Galena Biopharma, formerly RXi Pharmaceuticals Corporation, from November 2009 until April 2011. Prior thereto, he spent more than 10 years at Indevus Pharmaceuticals, Inc. serving most recently as executive vice president, chief business officer from September 2004 until the sale of the company to Endo Pharmaceuticals, Inc. in 2009. Prior to joining Indevus, from 1995 to 1997, Mr. Beerman was vice president responsible for health care at Technology Management and Funding. Mr. Beerman previously served in a variety of business development and scientific capacities at Creative BioMolecules, Sandoz AG, and Repligen. Mr. Beerman received an M.B.A. from Northeastern University's High Technology Program and a B.S. in molecular genetics from the University of Rochester.
Lucy Lu, M.D. Executive Vice President & Chief Financial Officer
Dr. Lu has served as our executive vice president and chief financial officer since February 2012. She joins the company from Citi Investment Research, where she was a senior biotechnology equity analyst from February 2007 until joining Coronado. At Citi, Dr. Lu was responsible for the coverage of small- and mid- capitalization stocks and the vetting of both public and private companies. Prior to Citigroup, Dr. Lu was a senior analyst at First Albany Capital as a Vice President and Principal from April 2004 to February 2007. She started her career at Lehman Brothers as an Associate of Healthcare Investment Banking. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.
Mr. Ritter has served as our senior vice president, finance and chief accounting officer since May 2011. He also served as acting chief financial officer until February 2012. Mr. Ritter has over 20 years of experience in the pharmaceutical industry. From September 2009 until joining us, he was an independent consultant, most recently serving as a financial consultant to Helicos BioSciences Corporation, an innovative genetic analysis technologies company, from January to May 2011. From 1994 to 2009, Mr. Ritter was the senior vice president of finance and chief accounting officer at Indevus Pharmaceuticals until the sale of the company to Endo Pharmaceuticals. Mr. Ritter has a B.A. from Syracuse University and an MBA from Babson College Graduate School of Business Administration.
Karin Hehenberger, M.D., PH.D. Executive Vice President & Chief Medical Officer
Dr. Hehenberger has served as our Executive Vice President & Chief Medical Officer since April 2012.
Prior to this, she served as our Senior Vice President of Scientific Affairs since December 2011. Dr.
Hehenberger has over 12 years of experience in the healthcare industry. Prior to joining Coronado,
Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research
Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial,
and commercial partners in the diabetes community. Prior to JDRF, Dr. Hehenberger worked at Johnson
& Johnson as Vice President of Metabolic Strategy and Business Development. Dr. Hehenberger
also has experience in public and private equity, having been a partner in Scandinavian Life Science
Venture, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, on the senior
management team of Eyetech Pharmaceuticals, and earlier in her career as a strategic management
consultant at McKinsey & Co. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska
Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin
Diabetes Center at Harvard Medical School.